Intellia Therapeutics, Inc. (NTLA)
13.72
-0.13
(-0.94%)
USD |
NASDAQ |
May 07, 16:00
13.78
+0.06
(+0.40%)
After-Hours: 07:30
Intellia Therapeutics Research and Development Expense (Annual) : 379.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Recursion Pharmaceuticals, Inc. | 425.27M |
| KalVista Pharmaceuticals, Inc. | 55.64M |
| Beam Therapeutics, Inc. | 409.62M |
| Novavax, Inc. | 336.82M |
| Tango Therapeutics, Inc. | 129.88M |